Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What? - Hallo friend NEWS AN INSPIRATION, In the article you read this time with the title Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What?, we have prepared well for this article you read and download the information therein. hopefully fill posts Article ECONOMY, Article HEALTH, Article POLITICS, Article SPORTS, Article TRAVELING, Article UPDATE, we write can understand. Well, happy reading.

Titre : Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What?
link : Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What?

Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What?

Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What?T. Joseph Mattingly II, PharmD, MBA1, Julia F. Slejko, PhD1, and C. Daniel Mullins, PhD1

DOI: 10.1177/1060028017722007 | First Published July 17, 2017

Full Text Article
Download PDF
Link provided by via @HenryEChang Twitter

Abstract

Background: Numerous economic models have been published evaluating treatment of chronic hepatitis C virus (HCV) infection, but none provide a comprehensive comparison among new antiviral agents.

Objective: Evaluate the cost-effectiveness of all recommended therapies for treatment of genotypes 1 and 4 chronic HCV.

Methods: Using data from clinical trials, observational analyses, and drug pricing databases, Markov decision models were developed for HCV genotypes 1 and 4 to compare all recommended drugs from the perspective of the third-party payer over a 5-, 10-, and 50-year time horizon. A probabilistic sensitivity analysis (PSA) was conducted by assigning distributions for clinical cure, age entering the model, costs for each health state, and quality-adjusted life years (QALYs) for each health state in a Monte Carlo simulation of 10 000 repetitions of the model.

Results: In the lifetime model for genotype 1, effects ranged from 18.08 to 18.40 QALYs and total costs ranged from $88 107 to $184 636. The lifetime model of genotype 4 treatments had a range of effects from 18.23 to 18.43 QALYs and total costs ranging from $87 063 to $127 637. Grazoprevir/elbasvir was the optimal strategy followed by velpatasvir/sofosbuvir as the second-best strategy in most simulations for both genotypes 1 and 4, with drug costs and efficacy of grazoprevir/elbasvir as the primary model drivers.

Conclusions: Grazoprevir/elbasvir was cost-effective compared with all strategies for genotypes 1 and 4. Effects for all strategies were similar with cost of drug in the initial year driving the results.

Keywords hepatitis C, cost-effectiveness, cost-utility, genotype 1, genotype 4

Thus articles Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What?

that is all articles Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What? This time, hopefully can provide benefits to you all. Okay, see you in another article post.

You are now reading the article Hepatitis C Treatment Regimens Are Cost-Effective: But Compared With What? the link address https://newsaninpiration.blogspot.com/2017/07/hepatitis-c-treatment-regimens-are-cost.html

Tweet

Subscribe to receive free email updates: